Journal of Clinical Endocrinology & Metabolism, Vol 77, 19-24, Copyright © 1993 by Endocrine Society

ARTICLES

Use of thyrotropin receptor (TSHR) mutants to detect stimulating TSHR antibodies in hypothyroid patients with idiopathic myxedema, who have blocking TSHR antibodies

S Kosugi, T Ban, T Akamizu, W Valente and LD Kohn
Cell Regulation Section, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892.

Deletions of residues 295-306, 299-301, and 387-395 of the TSH receptor, as well as point mutations of cysteine 301 or 390 to serine, and tyrosine 385 to phenylalanine or alanine, markedly diminish the ability of a transfected receptor to measure the activity of blocking TSH receptor autoantibodies (TSHRAbs) in patients with idiopathic myxedema and hypothyroidism, but not stimulating TSHRAbs in Graves' patients. This has allowed us to use these mutants to detect stimulating TSHRAb activity in the sera of hypothyroid patients with idiopathic myxedema who have blocking TSHRAbs. In 7 such patients, we show that 50% or more have significant stimulatory activity in cells transfected with mutant receptors, as evidenced by the ability of the immunoglobulin G to directly increase cAMP levels or to enhance the ability of TSH or a Graves' stimulating TSHRAb to increase cAMP levels. Three of the TSH receptor mutants, deletions of residues 295-306 and 387-395 and the point mutation of cysteine 301 to serine, are shown to be particularly useful in these assays and may be useful to clarify the pathogenetic role and clinical significance of stimulating TSHRAbs in patients with autoimmune thyroid disease who also have blocking TSHRAbs.

This article has been cited by other articles:

				N. G. Morgenthaler, S. C. Ho, and W. B. Minich Stimulating and Blocking Thyroid-Stimulating Hormone (TSH) Receptor Autoantibodies from Patients with Graves' Disease and Autoimmune Hypothyroidism Have Very Similar Concentration, TSH Receptor Affinity, and Binding Sites J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1058 - 1065. [Abstract] [Full Text] [PDF]

				W. B. Minich, C. Lenzner, A. Bergmann, and N. G. Morgenthaler A Coated Tube Assay for the Detection of Blocking Thyrotropin Receptor Autoantibodies J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 352 - 356. [Abstract] [Full Text] [PDF]

				A. P. Weetman Graves' Disease N. Engl. J. Med., October 26, 2000; 343(17): 1236 - 1248. [Full Text] [PDF]

				L. D. Kohn, K. Suzuki, W. H. Hoffman, D. Tombaccini, C. Marcocci, N. Shimojo, Y. Watanabe, N. Amino, B. Y. Cho, Y. Kohno, et al. Characterization of Monoclonal Thyroid-Stimulating and Thyrotropin Binding-Inhibiting Autoantibodies from a Hashimoto's Patient Whose Children Had Intrauterine and Neonatal Thyroid Disease J. Clin. Endocrinol. Metab., December 1, 1997; 82(12): 3998 - 4009. [Abstract] [Full Text] [PDF]

				W. B. Kim, H. K. Chung, H. K. Lee, L. D. Kohn, K. Tahara, and B. Y. Cho Changes in Epitopes for Thyroid-Stimulating Antibodies in Graves' Disease Sera During Treatment of Hyperthyroidism: Therapeutic Implications J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1953 - 1959. [Abstract] [Full Text] [PDF]